The acquisition of myPOLS Biotec complements Medix Biochemica’s leading portfolio of IVD raw materials and expands its reagent offerings for molecular diagnostics
The system is a compact new addition to the Roche Molecular portfolio, providing efficiency, simplicity and timely results to laboratories of all sizes.
Thermo Fisher Scientific expands diagnostics portfolio to support full qPCR assay development and testing workflow
BIL also holds an option to increase its equity stake by an additional 15%
First fully automated, cartridge-based companion diagnostic test for colorectal cancer patients approved in the United States
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide
The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
Subscribe To Our Newsletter & Stay Updated
